Exact Mass: 247.0391
Exact Mass Matches: 247.0391
Found 68 metabolites which its exact mass value is equals to given mass value 247.0391,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
Emtricitabine
Emtricitabine is only found in individuals that have used or taken this drug. It is a nucleoside reverse transcriptase inhibitor (NRTI) for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults. Emtricitabine works by inhibiting reverse transcriptase (RT), an enzyme that allows the virus to multiply by copying HIV RNA into new viral DNA. The drug competes with the reverse transcriptases natural substrate deoxycytidine 5-triphosphate and also becomes incorporated into viral DNA. This is a result of emtricitabine being a synthetic nucleoside analogue of cytidine. It is phosphorylated by cellular enzymes to form emtricitabine 5-triphosphate which competes with the natural substrate deoxycytidine 5-triphosphate and becomes incorporated into nascent viral DNA, resulting in early chain termination. By inhibiting HIV-1 reverse transcriptase, emtricitabine can help to lower the amount of HIV (viral load) in a patients body and can indirectly increase the number of immune system cells (T cells or CD4+ T-cells). Both of these changes are associated with healthier immune systems and a decreased likelihood of serious illness. Emtricitabine is always used in conjunction with other HIV medicine to treat people with HIV infection. J - Antiinfectives for systemic use > J05 - Antivirals for systemic use > J05A - Direct acting antivirals > J05AF - Nucleoside and nucleotide reverse transcriptase inhibitors C471 - Enzyme Inhibitor > C1589 - Reverse Transcriptase Inhibitor > C97452 - Nucleoside Reverse Transcriptase Inhibitor D000890 - Anti-Infective Agents > D000998 - Antiviral Agents > D018894 - Reverse Transcriptase Inhibitors D000890 - Anti-Infective Agents > D000998 - Antiviral Agents > D044966 - Anti-Retroviral Agents D004791 - Enzyme Inhibitors > D019384 - Nucleic Acid Synthesis Inhibitors D000890 - Anti-Infective Agents > D000998 - Antiviral Agents C254 - Anti-Infective Agent > C281 - Antiviral Agent CONFIDENCE standard compound; EAWAG_UCHEM_ID 3106 Same as: D01199
ent-Emtricitabine
4-hydroxy-4-(1H-indol-3-yl)-5-thioxoimidazolidin-2-one
5-Chlorosalicylanilide
CONFIDENCE standard compound; INTERNAL_ID 1371; DATASET 20200303_ENTACT_RP_MIX504; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4680; ORIGINAL_PRECURSOR_SCAN_NO 4677 CONFIDENCE standard compound; INTERNAL_ID 1371; DATASET 20200303_ENTACT_RP_MIX504; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4721; ORIGINAL_PRECURSOR_SCAN_NO 4719 ORIGINAL_ACQUISITION_NO 4721; CONFIDENCE standard compound; INTERNAL_ID 1371; DATASET 20200303_ENTACT_RP_MIX504; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_PRECURSOR_SCAN_NO 4719 CONFIDENCE standard compound; INTERNAL_ID 1371; DATASET 20200303_ENTACT_RP_MIX504; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4704; ORIGINAL_PRECURSOR_SCAN_NO 4701 CONFIDENCE standard compound; INTERNAL_ID 1371; DATASET 20200303_ENTACT_RP_MIX504; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4699; ORIGINAL_PRECURSOR_SCAN_NO 4697 CONFIDENCE standard compound; INTERNAL_ID 1371; DATASET 20200303_ENTACT_RP_MIX504; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4708; ORIGINAL_PRECURSOR_SCAN_NO 4706 CONFIDENCE standard compound; INTERNAL_ID 1371; DATASET 20200303_ENTACT_RP_MIX504; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4715; ORIGINAL_PRECURSOR_SCAN_NO 4713
Imidodicarbonimidicdiamide, N-(4-chlorophenyl)-, hydrochloride (1:1)
5-(3-(Methoxycarbonyl)pyridin-2-yl)-furan-2-carboxylic acid
4-(4-HYDRAZINYLPHENYL)-4H-1,2,4-TRIAZOLE DIHYDROCHLORIDE
6-(4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl)hexanoic acid
5-(2-(Methoxycarbonyl)pyridin-4-yl)-furan-2-carboxylic acid
(2-AMINO-5-CHLOROPHENYL)(3-HYDROXYPHENYL)METHANONE
methyl 3-oxo-3-(6-(trifluoromethyl)pyridin-3-yl)propanoate
2-(2,3-dihydro-1-benzofuran-5-yl)-1,3-thiazole-4-carboxylic acid
3-[(4-CHLOROPHENYL)METHYL]-PYRIDINE-4-CARBOXYLIC ACID
6-Chloro-2-(4-fluorophenyl)imidazo[1,2-b]pyridazine
5-(4-METHYL-2-NITRO-PHENYL)-FURAN-2-CARBOXYLIC ACID
2-methyl-6-[(2,2,2-trifluoroacetyl)amino]benzoic acid
4-[3-(Methoxycarbonyl)-1,2-oxazol-5-yl]benzoic acid
Imidodicarbonimidicdiamide, N-(2-chlorophenyl)-, hydrochloride (1:1)
5-(4-NITROPHENYL)FURAN-2-CARBOXYLIC ACID METHYL ESTER
4-Oxo-4-(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-6-yl)-2-butenoic acid
6-chloro-4-(1,2,4-triazol-1-yl)pyrido[3,2-d]pyrimidin-2-amine
3-(8-chloroquinoline-4-yl)acrylic acid methyl ester
1-(3-chlorophenyl)biguanide hydrochloride
m-CPBG (1-(3-Chlorophenyl)biguanide) hydrochloride is a selective 5-HT3 agonist. m-CPBG hydrochloride can be used for the research of neurological disease[1].
Emtricitabine
J - Antiinfectives for systemic use > J05 - Antivirals for systemic use > J05A - Direct acting antivirals > J05AF - Nucleoside and nucleotide reverse transcriptase inhibitors C471 - Enzyme Inhibitor > C1589 - Reverse Transcriptase Inhibitor > C97452 - Nucleoside Reverse Transcriptase Inhibitor D000890 - Anti-Infective Agents > D000998 - Antiviral Agents > D018894 - Reverse Transcriptase Inhibitors D000890 - Anti-Infective Agents > D000998 - Antiviral Agents > D044966 - Anti-Retroviral Agents D004791 - Enzyme Inhibitors > D019384 - Nucleic Acid Synthesis Inhibitors C254 - Anti-Infective Agent > C281 - Antiviral Agent Same as: D01199
Pyridoxamine 5-phosphate(1-)
An organophosphate oxoanion that is the conjugate base of pyridoxamine 5-phosphate. COVID info from COVID-19 Disease Map Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
